Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib

被引：0
|
作者：
Goldenberg, D. M. [1 ]
Cardillo, T. M. [1 ]
Govindan, S. V. [1 ]
Zalath, M. [1 ]
Arrojo, R. [1 ]
Sharkey, R. M. [1 ]
机构：
[1] Immunomedics Inc, Morris Plains, NJ USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P6-15-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-02
引用
收藏
页数：2
相关论文
共 36 条
  • [1] Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Starodub, A. N.
    Moroose, R. L.
    Isakoff, S. J.
    Ocean, A. J.
    Guarino, M. J.
    Berlin, J. D.
    Messersmith, W. A.
    Thomas, S. S.
    O'Shaughnessy, J. A.
    Kalinsky, K.
    Maurer, M.
    Chang, J. C.
    Forero, A.
    Traina, T.
    Gucalp, A.
    Wilhelm, F.
    Wegener, W. A.
    Maliakal, P.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2016, 76
  • [2] Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Zalath, Maria
    Mostafa, Ali
    Arrojo, Roberto
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2016, 76
  • [3] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Trisal, Preeti
    Arrojo, Roberto
    Liu, Donglin
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Goldenberg, David M.
    BIOCONJUGATE CHEMISTRY, 2015, 26 (05) : 919 - 931
  • [4] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
    Goldenberg, David M.
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Rossi, Edmund A.
    Sharkey, Robert M.
    ONCOTARGET, 2015, 6 (26) : 22496 - 22512
  • [5] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Vahdat, Linda T.
    Isakoff, Steven J.
    Guarino, Michael
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Mayer, Ingrid A.
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER, 2017, 123 (19) : 3843 - 3854
  • [6] The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises
    Guerra, Emanuela
    Alberti, Saverio
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (09)
  • [7] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Starodub, Alexander N.
    Shah, Nikita C.
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Guarino, Michael
    Abramson, Vandana
    Juric, Dejan
    Tolaney, Sara M.
    Berlin, Jordan
    Messersmith, Wells A.
    Ocean, Allyson J.
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2141 - +
  • [8] Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
    Sharkey, Robert M.
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Guarino, Michael
    Messersmith, Wells A.
    Berlin, Jordan D.
    Picozzi, Vincent J.
    Moroose, Rebecca
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [9] Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)
    Gray, Jhanelle E.
    Heist, Rebecca S.
    Starodub, Alexander N.
    Camidge, D. Ross
    Kio, Ebenezer
    Masters, Gregory
    Purcell, W. Thomas
    Guarino, Michael J.
    Misleh, Jamal
    Schneider, Charles J.
    Schneider, Bryan J.
    Ocean, Allyson J.
    Johnson, Tirrell
    Gandhi, Leena
    Kalinsky, Kevin
    Govindan, Serengulam V.
    Maliakal, Pius
    Mudenda, Boyd
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [10] Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).
    Tagawa, Scott T.
    Ocean, Allyson J.
    Lam, Elaine Tat
    Saylor, Philip James
    Bardia, Aditya
    Hajdenberg, Julio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
1234